Hepatocellular carcinoma is a primary malignancy of the liver; the majority of cases arise from underlying liver cirrhosis. Treatment of hepatocellular carcinoma incorporates a variety of multimodal approaches; advanced (metastatic) disease is treated with palliative intent. Bayer HealthCare/Amgen/Onyx’s Nexavar is the only agent approved for first-line advanced hepatocellular carcinoma, and Bayer HealthCare’s Stivarga and Bristol-Myers Squibb’s Opdivo (United States only) are approved as second-line treatments. The late-phase therapy pipeline for hepatocellular carcinoma is focused on the advanced setting and encompasses a diverse range of mechanisms of action (MOAs). Because the hepatocellular carcinoma therapy market is largely untapped, developers of efficacious drugs can reap high commercial rewards.

Questions Answered:

  • How large is the treatable hepatocellular carcinoma population, and how will drug-treatment rates change over time?
  • How is hepatocellular carcinoma currently treated, and what are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • Who are the key players in the late-phase development pipeline for hepatocellular carcinoma? Which agents or drug classes are most promising? What therapies of note are progressing in earlier phases?
  • Which emerging therapies do we forecast to enter the hepatocellular carcinoma market during the forecast period? What sales/uptake could they secure in this niche oncology indication?

Scope:

Market covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Eight country-specific interviews with thought leaders (medical oncologists and hepatologists).

Epidemiology: Diagnosed incident cases of hepatocellular carcinoma: early-stage hepatocellular carcinoma, intermediate-stage hepatocellular carcinoma, and advanced-stage hepatocellular carcinoma.

Population segments in market forecast: Early-stage hepatocellular carcinoma, intermediate-stage hepatocellular carcinoma, advanced first-line hepatocellular carcinoma, and advanced second-line hepatocellular carcinoma.

Emerging therapies: Phase III: 10 drugs; Phase II: 22 drugs; coverage of select Phase I and preclinical products.

Product Description: Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Related Reports

Hepatocellular Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

Hepatocellular carcinoma is a primary malignancy of the liver that commonly arises from liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx) was the only drug approved for advanced disease un...

View Details

Hepatocellular Carcinoma | Disease Landscape and Forecast | G7 | 2020

Hepatocellular carcinoma is a primary malignancy of the liver that commonly arises from liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx) was the only drug approved for advanced disease un...

View Details

Hepatocellular Carcinoma - Geographic Focus: China - Hepatocellular Carcinoma - China In-Depth (China)

MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised to experience substantial market growth. Availability of systemic targeted drugs is limited, with...

View Details

Hepatocellular Carcinoma - Unmet Need - Detailed, Expanded Analysis - Advanced Hepatocellular Carcinoma (US/EU5)

Hepatocellular carcinoma, the most common type of primary liver cancer, occurs as a results of chronic liver cirrhosis and has a five-year survival rate of only 18%. First-line advanced hepatocellu...

View Details